Mandate

Vinge advises Lunar in connection with the transfer of all customer relationships within its P2P business to SaveLend

April 11, 2023 Financial Regulatory M&A

Vinge advises Lunar Bank A/S in connection with the transfer of all customer relationships with investors and lenders within its P2P business and related trademark and domain names to SaveLend Group AB’s subsidiary SBL Finans AB (publ).

The transfer includes approximately 17,000 active investors, 7,000 active borrowers and an invested capital of approximately MSEK 450. Lunar has operated its P2P business since 2021. In order to streamline its business, Lunar has actively been looking for a new home for its P2P customers, both investors and borrowers. Through the transaction, all customer relationships will as of closing be taken over and managed through SaveLend Group’s own platform and customer service team. 

Completion is subject to the approval of the Danish Financial Supervisory Authority.

Vinge’s team mainly consisted of Filip Öhrner, Robin Fagerström (M&A) and Caroline Krassén (Financial Services).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026